TEW 7197

Drug Profile

TEW 7197

Alternative Names: EW-7197; NOV 1301; TEW7197

Latest Information Update: 24 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ewha Womans University
  • Developer Case Comprehensive Cancer Center; MedPacto; National OncoVenture
  • Class Aniline compounds; Antineoplastics; Fluorine compounds; Imidazoles; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Transforming growth factor beta type I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Myelodysplastic syndromes
  • Phase I Multiple myeloma; Solid tumours

Most Recent Events

  • 04 Jan 2018 Phase-I/II clinical trials in Myelodysplastic syndromes (Monotherapy, Second-line therapy or greater) in USA (PO) (NCT03074006)
  • 07 Nov 2017 TEW 7197 is still in phase I trials for Solid tumours (Late-stage disease) in USA (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top